SciBase Holding AB AI Stock Analysis
Want to see SE:SCIB full AI Analyst Report?
SciBase Holding AB (SCIB) AI Stock Analysis
SciBase Holding AB
(Nasdaq OMX AB:SCIB)
The overall score is at the minimum of 37, reflecting a convergence of extreme risks. The most significant factor is the company's critical financial state, characterized by massive cash burn that outpaces its impressive revenue growth, making its survival dependent on future financing. This fundamental weakness is mirrored by a deeply bearish technical trend, with the stock in a strong downtrend and showing no signs of reversal. The lack of positive earnings or valuation metrics provides no counterbalance to these risks.
SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 128.49M
- Dividend Yield
- ―
- Average Volume (3M)
- 10.94K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- -0.24
- Revenue Growth
- 54.94%
- EPS Growth
- 47.64%
- Country
- Sweden
- Employees
- 46
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
SciBase Holding AB Business Overview & Revenue Model
Company Description
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key...
SciBase Holding AB Financial Statement Overview
Summary
Financial health is precarious. While revenue growth is exceptional (TTM surge >800%), the company is deeply unprofitable with widening net losses and a critical cash burn rate (TTM operating cash flow of SEK -102.5M). A recent recapitalization has temporarily shored up the balance sheet, but the core business is not self-sustaining.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.68M | 40.46M | 29.70M | 23.25M | 17.89M | 11.73M |
| Gross Profit | 33.50M | 27.10M | 21.08M | 16.04M | 11.23M | 6.58M |
| EBITDA | -98.58M | -81.49M | -57.64M | -51.83M | -39.33M | -38.82M |
| Net Income | -104.45M | -87.06M | -61.13M | -55.59M | -39.90M | -41.69M |
Balance Sheet | ||||||
| Total Assets | 53.37M | 52.17M | 61.73M | 64.33M | 49.85M | 85.46M |
| Cash, Cash Equivalents and Short-Term Investments | 13.53M | 22.60M | 11.24M | 34.12M | 18.83M | 65.61M |
| Total Debt | 22.50M | 23.03M | 4.18M | 6.80M | 8.12M | 2.86M |
| Total Liabilities | 47.74M | 45.51M | 25.08M | 21.28M | 24.62M | 14.66M |
| Stockholders Equity | 5.64M | 6.66M | 36.65M | 43.06M | 25.24M | 70.80M |
Cash Flow | ||||||
| Free Cash Flow | -103.99M | -84.81M | -57.81M | -52.37M | -44.85M | -40.12M |
| Operating Cash Flow | -102.49M | -84.58M | -57.38M | -51.98M | -44.47M | -39.50M |
| Investing Cash Flow | -1.59M | -228.00K | -428.00K | -383.00K | -381.00K | -526.00K |
| Financing Cash Flow | 92.87M | 96.29M | 34.91M | 67.68M | -2.48M | 64.22M |
SciBase Holding AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 9.10 is below the 20-day moving average (MA) of 11.52, below the 50-day MA of 13.63, and below the 200-day MA of 27.56, indicating a bearish trend. The MACD of -1.35 indicates Positive momentum. The RSI at 19.12 is Positive, neither overbought nor oversold. The STOCH value of 6.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.
SciBase Holding AB Peers Comparison
Overall Rating
SE:SECT.B78Outperform
SE:PAX57Neutral
SE:SEZI55Neutral
SE:ACARIX45Neutral
SE:SPEC40Underperform
SE:SCIB37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | SEK 64.19B | 100.61 | 30.26% | 0.70% | 13.94% | 5.70% | |
| 57Neutral | SEK 1.55B | -304.31 | -1.22% | ― | 34.05% | -144.96% | |
| 55Neutral | SEK 525.88M | -5.39 | -35.44% | ― | 18.56% | 28.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | SEK 198.23M | -5.03 | -96.06% | ― | 40.61% | 32.63% | |
| 40Underperform | SEK 19.12M | -0.31 | -25.90% | ― | ― | 78.15% | |
| 37Underperform | SEK 128.49M | -0.68 | -415.20% | ― | 54.94% | 47.64% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SCIB | SciBase Holding AB | 9.10 | -9.99 | -52.34% | |
| SE:PAX | Paxman AB | 66.40 | 6.40 | 10.67% | |
| SE:SEZI | Senzime AB | 3.35 | -1.73 | -34.15% | |
| SE:SPEC | SpectraCure AB | 0.01 | -0.11 | -90.08% | |
| SE:SECT.B | Sectra AB Class B | 329.00 | 53.60 | 19.46% | |
| SE:ACARIX | Acarix AB | 0.16 | -0.11 | -41.76% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
